Dassault Systèmes’ 3DEXPERIENCE Platform Adopted by Olympus Technologies Singapore

Leveraging New “Licensed to Cure” Industry Solution Experience to Harmonize Product Development Operations in a Single Environment

SINGAPORE, December 18, 2012 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, today announced that Olympus Technologies Singapore Pte Ltd, a leading endoscope manufacturer, has selected Dassault Systèmes’ 3DEXPERIENCE platform for the development of its medical devices. The new “Licensed to Cure” industry solution experience will be deployed to create a single environment, allowing to eliminate scattered processes and data, and to “embed” regulations as an asset, optimizing quality and compliance.

Olympus Technologies Singapore has standard operating procedures in developing engineering and software system documentation for their medical device manufacturing. “Licensed to Cure” will help them simplify those procedures by providing a single source of information to always get relevant, up-to-date information and establish true collaboration with the same, accurate set of product data. In addition, Olympus Technologies Singapore will be able to reduce new product time to market and streamline regulatory filings by creating an end-to-end, traceable and compliant product development process directly linked to quality management.

“Dassault Systèmes’ 3DEXPERIENCE platform gives us centralized control and management of all product lifecycle information, enabling real time sharing and collaboration for all functions,” said Lim HN, managing director, Olympus Technologies Singapore. “Being able to combine engineering, quality, and regulatory compliance business processes, we have moved closer towards becoming the R&D and manufacturing centre of choice for our customers.”

“The shifting financial, regulatory and globalization landscapes faced by medical devices manufacturers really call for a comprehensive business experience that can keep up with complexity, lower cost, quality, and compliance at once,” said Monica Menghini, Executive Vice President, Industry and Marketing, Dassault Systèmes. “ Our new “Licensed to Cure” industry solution experience is exactly meeting this challenge by allowing companies like Olympus Technologies Singapore to manage their business objectives in a complex regulatory environment while meeting consumers’ expectations for safe products.”

For more information on “Licensed to Cure” and all of Dassault Systèmes’ industry solution experiences for Life Sciences: http://www.3ds.com/solutions/life-sciences/overview/